2028 and Food and Drug Administration

USP General Chapter —Glass revised

European Pharmaceutical Review

NOVEMBER 14, 2023

In response to supply chain challenges, including shortages of critical glass vials for products like COVID-19 vaccines and parenteral drugs, the Packaging and Distribution Expert Committee (PD EC) has made a significant revision of United States Pharmacopeia (USP) General Chapter <660>—Glass.

Food and Drug Administration

Food and Drug Administration Manufacturing Distribution Food

Alimera Sciences buys US rights to EyePoint’s Yutiq

Pharmaceutical Technology

MAY 19, 2023

It received approval from the US Food and Drug Administration in October 2018. EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028.

Food and Drug Administration

Food and Drug Administration Pharmaceutical Food Sales

Astellas to accelerate ocular disease treatments with $5.9 billion acquisition

European Pharmaceutical Review

MAY 2, 2023

billion in 2028, according to GlobalData’s Pharma Intelligence Center. Limiting progression of geographic atrophy via C5 inhibition Specifically, ACP, a complement C5 inhibitor, is an investigational drug for GA secondary to AMD and has significant potential to deliver value to a large and underserved patient base, according to Astellas.

Food and Drug Administration

Food and Drug Administration Pharma FDA Sales

Webinars

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

MORE WEBINARS

MSD secures full approval for Keytruda’s use in MSI-high solid tumours

Pharmaceutical Technology

MARCH 30, 2023

The drug is approved in several indications, including advanced melanoma, metastatic non-small cell lung cancer (NSCLC), and relapsed classical Hodgkin lymphoma (cHL). As per GlobalData’s consensus forecasts, the drug is estimated to yield global sales of $34.79 billion in 2028. billion in 2028.

Food and Drug Administration

Food and Drug Administration FDA Sales Food

Viatris to acquire Oyster Point and Famy Life Sciences

Pharmaceutical Technology

NOVEMBER 8, 2022

Oyster Point Pharma introduced Tyrvaya, a nasal spray approved by the Food and Drug Administration (FDA) to treat dry eye disease, in November last year. These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. Famy Life Sciences has an ophthalmology portfolio that complements Viatris.

Food and Drug Administration

Food and Drug Administration Leads Food Pharma

Acute lymphocytic leukaemia leads in cell therapy clinical development

Pharmaceutical Technology

JULY 12, 2022

The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

Leads

Leads Food and Drug Administration Marketing Sales

An increasing impact of BCMA-targeting biologics in multiple myeloma

Pharmaceutical Technology

SEPTEMBER 2, 2022

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

Food and Drug Administration

Food and Drug Administration FDA Sales Marketing

More big wins for the AstraZeneca-Daiichi Sankyo collaboration

Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. GlobalData estimates that global annual sales for datopotamab deruxtecan in the NSCLC setting will exceed $500m in 2028.

Food and Drug Administration

Food and Drug Administration Sales Patients Food

Key developments: mRNA vaccines and therapeutics

European Pharmaceutical Review

FEBRUARY 14, 2023

A key benefit of mRNA therapeutics is that manufacturing time is fast compared to antibodies or protein-based drugs. The research also identified other challenges for mRNA therapeutics’ delivery , including their high cost, susceptibility to degradation by ribonucleases and limitations with drug delivery systems.

Food and Drug Administration

Food and Drug Administration Medicine Safety Consulting

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

OCTOBER 17, 2022

million by 2028. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. Now, the demand for such equipment is on track to grow exponentially. Development Of New Biotech Coating In Orthopedic Medical Devices.

Medical

Medical Food and Drug Administration Healthcare Healthcare

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

OCTOBER 17, 2022

million by 2028. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. Now, the demand for such equipment is on track to grow exponentially. Development Of New Biotech Coating In Orthopedic Medical Devices.

Medical

Medical Food and Drug Administration Healthcare Healthcare

A history of blood cancer treatment

pharmaphorum

SEPTEMBER 13, 2022

Just over a decade after it was developed by biochemist Nicholas Lyndon, Imatinib received US Food and Drug Administration (FDA) approval in 2001. Since then, it has transformed the treatment of chronic myeloid leukaemia and non-Hodgkin’s lymphoma. 2002 – Emergence of CAR-T therapy.

Food and Drug Administration

Food and Drug Administration Patients Engineering Physicians

MSD’s Keytruda use in adenocarcinoma could be limited based on biomarker

Pharmaceutical Technology

JUNE 16, 2023

In 2021, as part of the same Keynote-811 trial, the US Food and Drug Administration (FDA) granted accelerated approval to Keytruda for treating locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, in combination with trastuzumab and chemotherapy containing fluoropyrimidin and platinum.

Food and Drug Administration

Food and Drug Administration FDA Prospecting Food

Three biggest threats to healthcare

World of DTC Marketing

APRIL 7, 2022

By 2028, these costs are expected to climb to $6.2 Launch prices of new cancer drugs in the U.S. Food and Drug Administration (FDA). billion estimated cumulative spending on the new oral targeted cancer drugs by the end of 2018. THREAT 3: RISING HEALTHCARE COSTS. A study reported that U.S. billion in 1970.

Healthcare

Healthcare Healthcare Food and Drug Administration Government

Pharma Rep Focus

USP General Chapter —Glass revised

Alimera Sciences buys US rights to EyePoint’s Yutiq

Webinars

Trending Sources

Astellas to accelerate ocular disease treatments with $5.9 billion acquisition

Webinars

MSD secures full approval for Keytruda’s use in MSI-high solid tumours

Viatris to acquire Oyster Point and Famy Life Sciences

Acute lymphocytic leukaemia leads in cell therapy clinical development

An increasing impact of BCMA-targeting biologics in multiple myeloma

More big wins for the AstraZeneca-Daiichi Sankyo collaboration

Key developments: mRNA vaccines and therapeutics

Emerging Trends in Orthopedic Medical Device Industry

Emerging Trends in Orthopedic Medical Device Industry

A history of blood cancer treatment

MSD’s Keytruda use in adenocarcinoma could be limited based on biomarker

Three biggest threats to healthcare

Stay Connected